SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (7943)5/28/2000 2:01:00 PM
From: tuck  Read Replies (3) of 9719
 
V1,

What happens to Attendade and the whole Ritalin market when BLSI's Altropane imaging agent goes commercial (sometime in the next year or two) for ADHD, the primary indication for Ritalin? Altropane supposedly provides an objective, biochemical basis for diagnosis of ADHD. It is likely that ADHD is overdiagnosed and Ritalin overprescribed. Should Altropane reveal this, the Ritalin market is overstated. Unless Attendade isn't addictive (can't say I know the drug), so are CELG's expected revenues from Attendade.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News